AVITA Medical to Announce First Quarter 2024 Financial Results VALENCIA, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that it will report its first quarter 2024 financial results after the close of the U.S. financial markets on Monday, May 13, 2024. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Tuesday, May 14, 2024, at 6:30 a.m. Australian Eastern Standard ...
AVITA Medical Updates Expected First Quarter 2024 Revenue VALENCIA, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced an update to its expected commercial revenue for the first quarter of 2024 and reaffirmed expectations for full-year 2024 revenue at the lower end of the previously provided guidance of US$78.5 million to US$84.5 million. For the quarter ended March 31, 2024, AVITA Medical now expects comm...
AVITA Medical Submits Response to FDA, Resuming Review Clock for RECELL GO PMA Supplement VALENCIA, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced it has submitted its response to the U.S. Food and Drug Administration (FDA) for additional information requested in connection to its premarket approval (PMA) supplement for RECELL GO™. This submission resumes the substantive interactive review process under ...
AVITA Medical to Present at TD Cowen 44th Annual Health Care Conference VALENCIA, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that David O’Toole, Chief Financial Officer, will present at TD Cowen’s 44th Annual Health Care Conference on Tuesday, March 5, 2024, at 9:50 a.m. Eastern Time. A live audio webcast of the presentation will be available under the Events & Presentations section of AVITA Medical...
AVITA Medical to Host Investor Webinar Briefing VALENCIA, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O’Toole, Chief Financial Officer, on February 27, 2024, at 2:00 p.m. (PST) / February 28, 2024, at 9:00 a.m. (AEDT). The webinar presentation will cover financial...
AVITA Medical Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance VALENCIA, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today reported financial results for the fourth quarter and full-year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights Commercial revenue increased approximately 50% to $14.1 million compared to the same period in 2022Gross prof...
AVITA Medical to Announce Fourth Quarter and Full Year 2023 Financial Results VALENCIA, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices and autologous cellular therapies for skin restoration, today announced that it will report its fourth quarter and full year 2023 financial results after the close of the U.S. financial markets on Thursday, February 22, 2024. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, February 23,...
AVITA Medical Announces Exclusive Distribution Agreement with Stedical Scientific VALENCIA, Calif., Jan. 10, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a commercial-stage regenerative medicine company focused on first-in-class devices and autologous cellular therapies for skin restoration, today announced it has entered into an exclusive multi-year distribution agreement with Stedical Scientific, Inc. to commercialize PermeaDerm® Biosynthetic Wound Matrix in the United States. PermeaDerm is cleared by the Food and Drug Administration as a transp...
AVITA Medical Announces Preliminary 2023 Financial Highlights, Provides 2024 Financial Guidance and Business Update VALENCIA, Calif., Jan. 10, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a commercial-stage regenerative medicine company focused on first-in-class devices and autologous cellular therapies for skin restoration, today announced preliminary unaudited financial highlights for the fourth quarter and full-year 2023, provided financial guidance for the first quarter and full-year 2024, and announced completion of patient enrollment in its ...
AVITA Medical to Present at the 42nd Annual J.P. Morgan Healthcare Conference VALENCIA, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices and autologous cellular therapies for skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024, at 11:15 a.m. Pacific Time. A live audio webcast of the presentation will be available under the Events & Presentations sec...
AVITA Medical to Host Investor Webinar Briefing VALENCIA, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O’Toole, Chief Financial Officer, on December 5, 2023, at 2:00 p.m. (PST) / December 6, 2023, at 9:00 a.m. (AEDT). ...
AVITA Medical to Present at the Piper Sandler 35th Annual Healthcare Conference VALENCIA, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the Piper Sandler 35th Annual Healthcare Conference in New York on Tuesday, November 28, 2023, at 1:00 p.m. Eastern Time. A live webcast of the presentation will be ...
AVITA Medical Updates Full Year 2023 Guidance VALENCIA, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced an update to its full year 2023 guidance. This update is a result of slower-than-anticipated progression through the customer’s Value Analysis Committee (VAC) processes, driven by the expanded label applications of its newest indication, full-thickness skin d...
AVITA Medical Reports Third Quarter Financial Results with 51% Revenue Growth over the Same Period the Prior Year VALENCIA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today reported financial results for the third quarter September 30, 2023. Financial Highlights and Recent Updates Commercial revenue of $13.5 million, an approximately 51% increase compared to $9.0 m...
AVITA Medical Announces Distribution Partnership with PolyMedics Innovations to Expand to Europe VALENCIA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced it has entered into a distribution agreement with PolyMedics Innovations GmbH, to strategically expand its global presence to Europe. Under the terms of the agreement, PolyMedics Innovations will serve as ...
AVITA Medical to Announce Third Quarter 2023 Financial Results VALENCIA, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that it will report its third quarter 2023 financial results after the close of the U.S. financial markets on Thursday, November 9, 2023. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, November 10, 2023, at ...
AVITA Medical Announces Preliminary Third Quarter 2023 Financial Highlights and Secures up to $90 million of Non-Dilutive Debt Financing with OrbiMed to Support Growth Initiatives Preliminary commercial revenue of $13.5 million for the third quarter 2023; full year 2023 guidance confirmed$40 million funded at close; $50 million of additional non-dilutive capital available at the Company’s option, based on the achievement of certain revenue thresholdsCapital from the transaction will support execution of strategic expansion and fuel continued growth VALENCIA, Calif., Oct. 18, 2023 (GLOBE ...
AVITA Medical Receives Best Product Award at the American Association for the Surgery of Trauma VALENCIA, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, is pleased to announce that the RECELL® System won Best Product for the second year in a row at the Annual Meeting of the American Association for the Surgery of Trauma (AAST). In its 82nd year, the annual meeting attracts over 700 physicia...
AVITA Medical to Present at the Cantor Global Healthcare Conference VALENCIA, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the 2023 Cantor Fitzgerald Global Healthcare Conference in New York on Tuesday, September 26, 2023, at 11:05 a.m. Eastern Time. A live webcast of the presentation will be available under the...
AVITA Medical to Participate in Upcoming Investor Conferences VALENCIA, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that its management team will participate in the following upcoming investor conferences: Morgan Stanley 21st Annual Global Healthcare Conference, New York, NYWednesday, September 13, 2023, including a fireside chat at 2:15 p.m. Eastern Time Lake Stree...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.